Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of EDP-938 on the Pharmacokinetics of Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of EDP-938 on the Pharmacokinetics of Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zelicapavir (Primary) ; Dabigatran etexilate; Midazolam; Rosuvastatin; Tacrolimus
  • Indications Respiratory syncytial virus infections
  • Focus Pharmacokinetics
  • Sponsors Enanta Pharmaceuticals

    • Most Recent Events

    • 12 Oct 2021 Status changed from recruiting to completed.
    • 10 Mar 2021 Number of arms changed from 3 to 4. Drug Midazolam and experimental arm: EDP-938 and midazolam interaction (Part 4) added to study protocol. Planned number of patients increased.
    • 10 Mar 2021 Planned number of patients changed from 72 to 96.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top